Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The Bcl-2 family regulates apoptosis, a key process in cancer.
• Targeting anti-apoptotic proteins is a promising anti-cancer strategy.
• Venetoclax (Bcl-2 inhibitor) is approved for chronic lymphocytic leukemia (CLL).

Purpose of the Study:

• To review the biological function and protein structure of BCL2A1/Bfl-1.
• To discuss the therapeutic potential of targeting Bfl-1.
• To summarize current Bfl-1 inhibitory peptides and small molecules.

Main Methods:

• Literature review of Bfl-1 biological function and structure.
• Analysis of therapeutic potential for Bfl-1 targeting.
• Compilation of reported Bfl-1 inhibitors.

Main Results:

• Bcl-2 family members are critical regulators of apoptosis.
• Bcl-2 inhibitor Venetoclax is effective for CLL treatment.
• Development of BCL2A1/Bfl-1 inhibitors is lagging, with no ideal candidates identified yet.

Conclusions:

• Bfl-1 is an important anti-apoptotic target for cancer therapy.
• Further research into Bfl-1 inhibitors is needed.
• This review provides a reference for future Bfl-1 drug discovery efforts.